FUJIFILM Toyama Chemical Co. Ltd has granted Dr Reddy’s the exclusive rights to sell & produce Favipiravir (AVIGAN) 200 mg Tablets in India.
Dr Reddy’s Laboratories Ltd, along with its subsidiaries together referred to as “Dr Reddy’s” today declared the launch of AVIGAN® (Favipiravir) 200 mg Tablets.
Now Dr Reddy has special Rights to produce, sell and deal out AVIGAN (Favipiravir) 200 mg Tablets in India, licence granted by FUJIFILM Toyama Chemical Co. Ltd.
Drugs Controller General of India (DCGI) has been approved AVIGAN® (Favipiravir) for the treatment of Covid-19 patients with some moderation.
M V Ramana, Chief Executive Officer, Dr Reddy’s Laboratories (Branded Markets) said “We are Glad to bring this exclusive medicine to the covid-19 patients in India. We launces this medicine with high quality and potency to provide a Fruitful treatment pack of 122 tablets with a two-years life option to the Covid-19 patients in India.”